The Role of Transthoracic Echocardiography in Diagnosis of Pulmonary Hypertension of Infants With Bronchopulmonary Dysplasia

Related Clinical Trial
The Role of Transthoracic Echocardiography in Diagnosis of Pulmonary Hypertension of Infants With Bronchopulmonary Dysplasia Body Weight Growth After Birth and Bronchopulmonary Dysplasia Outcome of Extremely Preterm Infants Who Received Systemic Postnatal Corticosteroid for Bronchopulmonary Dysplasia Comparison of the Acute Effects of Chest Physiotherapy Methods Applied in Different Positions in Preterm Newborns Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants Impact of Steroid, Diuretic, and Fluid Use on BPD Outcomes Ultrasound Assessment of Diaphragmatic Function in Infants With BPD Ventilation-perfusion (V/Q) Ratio and Alveolar Surface Area in Preterm Infants Nasal High-frequency Oscillatory Ventilation (NHFOV) for Ventilated Newborn Infants With BPD Prone Versus Supine Positioning and the Impact on Bronchopulmonary Dysplasia in Very Low Birth Weight Infants. Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia. NAVA vs. CMV Crossover in Severe BPD CPAP Or Nasal Cannula Oxygen for Preterm Infants: A Randomized Controlled Trial Lung Ultrasound for Early Identification of Preterm Infants With Bronchopulmonary Dysplasia Phase 1b/2 Study on AT-100 Intervention (rhSP-D) in Preterm Neonates at High Risk for Development of Bronchopulmonary Dysplasia (BPD) Inhaled Treatment for Bronchopulmonary Dysplasia Phase 1 Trial of Inhaled Tobramycin in BPD The Budesonide in Babies (BiB) Trial Follow-up Results of Newborns With Tracheostomy Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia Prolonged Outcomes After Nitric Oxide (PrONOx) A Study of Tobacco Smoke and Children With Respiratory Illnesses Delivery Room CPAP in Extremely Low Birth Weight Infants Dexamethasone Therapy in VLBW Infants at Risk of CLD Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children Estimating Length of Endotracheal Tube Insertion Using Gestational Age or Nasal-Tragus Length in Newborn Infants MRI as a Means to Measure Lung Function: Non-Invasive Imaging in Neonates and Children Seattle-PAP Bubble Nasal CPAP and Work of Breathing High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths: Effects on Blood Oxygenation and Stability of Oxygenation Comparing Two Different Modes of Ventilation in Pretem Neonates Bilevel VG and PRVC High Frequency Ventilation in Premature Infants (HIFI) Early Caffeine in Preterm Neonates High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths: Effects on Lung Volume Monitored by Electric Tomography Impedance. Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants Non-invasive Respiratory Support in Preterm Infants Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates Randomized Trial of Nasal Continuous Positive Airway Pressure or Synchronized Nasal Ventilation in Premature Infants. The Effect of Surfactant Dose on Outcomes in Preterm Infants With RDS Work of Breathing During Non-invasive Ventilation in Premature Neonates Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants Intratracheal Budesonide/Surfactant Prevents BPD Bronchopulmonary Disease (BPD) Patient Registry Premature Birth and Its Sequelae in Women Inhaled NO in Prevention of Chronic Lung Disease The Effects of Position on the Oxygenation Instability of Premature Infants as Documented by SpO2 Histograms Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide Continuous Positive Airway Pressure Via Binasal Prong vs Nasal Mask: a Randomised Controlled Trial Randomized Trial of Hydrocortisone in Very Preterm High-Risk Infants Early NCPAP Before Surfactant Treatment in Very Preterm Infants With RDS Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome Continuous Versus Intermittent Bolus Feeding in Very Preterm Infants – Effect on Respiratory Morbidity Feasibility and Impact of Volume Targeted Ventilation in the Delivery Room Growth of Airways and Lung Tissues in Premature and Healthy Infants Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants Assessment of Lung Structure and Function of Infants Born Prematurely Post-hospitalization Nursing Effectiveness (PHONE) Study Assessment of the Pulmonary Diffusion Capacity in Healthy Infants and Infants With Chronic Lung Disease NCPAP + Heliox as a Treatment for Infant Respiratory Distress Syndrome (RDS) Neurotrophin Expression in Infants as a Predictor of Respiratory and Neurodevelopmental Outcomes Inhaled Beclomethasone to Prevent Chronic Lung Disease Work of Breathing in Premature Infants at Discharge Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome Hydrocortisone for BPD Clinic Features and Outcome of BPD (SGBPD) Neolifes Heart – Pulmonary Hypertension in Preterm Children Thrombocytopoiesis and Platelet Homeostasis in Infants With Bronchoplumonary Dysplasia Management of Hyponatremia in Preterm Infants on Diuretics Steroids and Surfactant in Extremely Low Gestation Age Infants Dose Escalation Trial Respiratory Outcome at Adolescence of Very Low Birthweight Infants Surfactant Administration During Spontaneous Breathing Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease Developmental Sequelae of Severe Chronic Lung Disorders Long-term Safety and Efficacy Follow-up Study of PNEUMOSTEM® in Patients Who Completed PNEUMOSTEM® Phase-I Study Indoor Air Quality and Respiratory Morbidity in School-Aged Children With BPD Study of Nasal Ventilation In Preterm Infants To Decrease Time on The Respirator Improving Prematurity-Related Respiratory Outcomes at Vanderbilt Study of Inhaled Nitric Oxide (iNO) and Respiratory Outcomes in Late Preterm Infants Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial Follow-up Safety and Efficacy Evaluation on Subjects Who Completed PNEUMOSTEM® Phase-II Clinical Trial Tidal Neonatal NO, Vitamins A and D, and Infant Lung Disease – The AD-ON Study Nasal Mask and Prong Use in Non-invasive Ventilation for Newborns Azithromycin in the Prevention of Lung Injury in Premature Newborn Randomized Control Trial: Synchronized Non-invasive Positive Pressure Ventilation Versus Non Synchronized Non Invasive Positive Pressure Ventilation in Extremely Low Birth Weight Infants Neurally Adjusted Ventilatory Assist vs Proportional Assist Ventilation MRI in BPD Subjects A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD Hypercapnia and Its Association With Long-term Respiratory Morbidities in Premature Infants With Chronic Lung Disease Early Versus Late Caffeine for ELBW Newborns Assessment of Lung Aeration at Birth MRI of Lung Structure and Function in Preterm Children BPD Saturation TARgeting Use of Human Milk Cream to Decrease Length of Stay in Extremely Premature Infants Effect of Synchronized vs. Continuous HFNC Using NAVA on WOB in Infants With BPD Antecedents of Bronchopulmonary Dysplasia Pulmonary Outcomes of Bronchopulmonary Dysplasia in Young Adulthood Aerosolized Albuterol Use in Severe BPD Late Sequelae of Bronchopulmonary Dysplasia Montelukast in Very Low Birthweight Infants Preterm Infant Inhaled Albuterol Dosing 129Xe MRI in Pediatric Population With BPD Investigation of Polymorphisms in Bronchopulmonary Dysplasia In Turkish Population Pulmonary MRI of Ex-preterm Children With and Without BPD To Understand Risk of Emphysematous Changes Comparison of Classification Standards of BPD in Premature Infants Inhaled Corticosteroids for Treatment of Bronchopulmonary Dysplasia Safety of Sildenafil in Premature Infants Phase II Pilot Study of Early Cortisol Replacement to Prevent Bronchopulmonary Dysplasia Intratracheal Umbilical Cord-derived Mesenchymal Stem Cells for Severe Bronchopulmonary Dysplasia Phase III Randomized, Double-Blind Study of Dexamethasone Vs Dexamethasone/Methylprednisolone Vs Placebo for Bronchopulmonary Dysplasia Impact of an Exercise Program for Children Aged 4 to 6 Years With Bronchopulmonary Dysplasia Trial II of Lung Protection With Azithromycin in the Preterm Infant Forced Oscillometry in Infants With Bronchopulmonary Dysplasia The Efficacy and Safety of Montelukast Sodium in the Prevention of Bronchopulmonary Dysplasia L-citrulline and Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia Enteral Zinc to Improve Growth in Infants at Risk for Bronchopulmonary Dysplasia Fluid Filled Lung Oxygenation Assistance Trial Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia Predictors of Pulmonary Hypertension Risk in Premature Infants With Bronchopulmonary Dysplasia Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia Risk Factors in Bronchopulmonary Dysplasia (Newborn Lung Project) Pilot Study of Topical Steroid for Prevention of Chronic Lung Disease in Extremely Premature Infants. Bronchopulmonary Dysplasia: From Neonatal Chronic Lung Disease to Early Onset Adult COPD Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia Benchmarking Initiative to Reduce Bronchopulmonary Dysplasia Physiologic Definition of Bronchopulmonary Dysplasia Safety and Efficacy of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD) – a US Study Inhaled Nitric Oxide for Pulmonary Hypertension and Bronchopulmonary Dysplasia Human Mesenchymal Stem Cells For Infants At High Risk For Bronchopulmonary Dysplasia SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants. Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD) Mesenchymal Stem Cells for The Treatment of Bronchopulmonary Dysplasia in Infants p16Ink4a in Bronchopulmonary Dysplasia in Children Transpyloric Feeding in Severe Bronchopulmonary Dysplasia Follow-Up Study of Mesenchymal Stem Cells for Bronchopulmonary Dysplasia Phase 1 Intravenous Citrulline for the Prevention of Bronchopulmonary Dysplasia in Preterm Infants Epidemiological Study for Bronchopulmonary Dysplasia (BPD) in China PREMILOC Trial to Prevent Bronchopulmonary Dysplasia in Very Preterm Neonates Stem Cells for Bronchopulmonary Dysplasia Hydrotherapy in Premature Infants With Bronchopulmonary Dysplasia Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Prospective Study on Plasma Pro-endothelin-1 in Predicting Bronchopulmonary Dysplasia Interest of Pulmonary Ultrasound to Predict Evolution Towards Bronchopulmonary Dysplasia in Premature Infants at Gestational Age Less Than or Equal to 34 Weeks of Gestation Safety and Efficacy Evaluation of PNEUMOSTEM® Treatment in Premature Infants With Bronchopulmonary Dysplasia Inhaled Extra-fine Hydrofluoalkane-beclomethasone (QVAR) in Premature Infants With Bronchopulmonary Dysplasia (BPD) Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia Study to Justify Steroid Use in Preterm Neonates to Prevent Bronchopulmonary Dysplasia Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia. Human Mesenchymal Stem Cells For Bronchopulmonary Dysplasia Human Mesenchymal Stem Cells For Moderate and Severe Bronchopulmonary Dysplasia Genetic Susceptibility for Bronchopulmonary Dysplasia in Preterm Infants Respiratory Management of Preterm Infants and Bronchopulmonary Dysplasia

Brief Title

The Role of Transthoracic Echocardiography in Diagnosis of Pulmonary Hypertension of Infants With Bronchopulmonary Dysplasia

Official Title

Pulmoner Hipertansiyon gelişmiş Bronkopulmoner Displazili Pretermlerin Ekokardiyografik ve Biyokimyasal değerIendirilmesi

Brief Summary

      Pulmonary hypertension may develop in premature newborn infants due to impaired lung
      development. The diagnosis of this disease can actually be made with interventional methods.

      In this study, we evaluated the importance of echocardiographic examination and blood
      laboratory tests in diagnosing this disease.
    

Detailed Description

      Bronchopulmonary dysplasia diagnosis was done by the same neonatologist according to the
      criteria published by the American National Institutes of Health (NIH) in 2001.

      Demographic data of patients like: birth weight, gender, gestational age; neonatal morbidity
      like: surfactant administration, PDA and its treatment, duration of mechanical ventilation,
      diuretic usage, intraventricular hemorrhage and its grade, necrotizing enterocolitis (NEC)
      and its severity, any surgical procedures and late-onset sepsis were recorded.

      Moreover; maternal and perinatal risk factors like presence of chorioamnionitis, maternal
      hypertension and administration of antenatal steroids were also recorded.

      Echocardiography:

      Echocardiographic measurements were performed with a GE Vivid-7 pro equipped with a 3-7 MHz
      for 2-dimensional and color flow Doppler mapping by the same pediatric cardiologist.

      Investigations were done in parasternal long, short axis, four chamber, five chamber views
      using M mode and Doppler wave. Two-dimensional measurements were done according to the
      guidelines of American Society of Echocardiography. M mode views were obtained in parasternal
      long axis by putting cursor between mitral valve and apical to tips of the MV leaflets.
      Ejection fraction and end diastolic or end systolic volumes were calculated using the
      Teicholtz (Teich) method. Estimated Pulmonary artery systolic pressure can be determined by
      using the modified Bernoulli equation: 4V2, where V is the maximum velocity of the tricuspid
      valve regurgitation jet, measured by continuous wave Doppler, added to the estimated right
      atrial pressure.

      The echocardiography parameters showing pulmonary hypertension are tricuspid velocity, mean
      pulmonary artery pressure (PAP), pulmonary vascular resistance, pulmonary acceleration time,
      pulmonary velocity time integral, fraction of area changes of Right ventricle (RV), RV
      myocardial performance index (TEI). Severe pulmonary hypertension affects not only RV but
      also LV systolic functions. Therefore we measured Left Ventricle (LV) eccentricity index and
      LV TEI parameters in order to see whether they were affected in patients w BPD and PHT.

      Pulmonary vascular resistance (PVR) can be measured using Tricuspid Velocity (m/s) and
      Velocity Time IntegralRVOT (cm) PVR (Wood units) = 10 × (TRV/VTIRVOT) + 0.16. Here, a
      TRV/VTIRVOT<0.2 corresponds approximately to a PVR of <2 Wood Units [8].

      Left Ventricular Eccentricity index (EI), measured at end-systole and end-diastole, from the
      parasternal short axis 2D image at the mid-papillary muscle level. The formula (EI=D2/D1) was
      used where D1 is the ventricular diameter perpendicular to the interventricular septum
      bisecting D2: the diameter parallel to the interventricular septum [9].

      RV systolic dysfunction occurs in PHT and shown by RV Fraction of Shortening (FS), tricuspid
      annular plane systolic excursion (TAPSE) and Inferior vena cava distensibility index.

      Inferior vena cava distensibility index is calculated by measuring the Dmax and Dmin of IVC
      from the subcostal view, and IVCDI exceeding 18% has been reported to be predictive of fluid
      responsiveness in adults, and it is often extrapolated in children as well.
      IVCDI=Dmax-Dmin/Dmin [10].

      First echocardiograms were performed at 36 to 38 weeks' post-menstrual age (PMA) for
      screening later repeated at 1, 3, 6 months after the first echocardiogram. Measurements were
      made during 3 consecutive cycles and mean values were used in statistical analysis.

      Pulmonary hypertension diagnosis was done according to presence of at least one of the
      following criteria [11]: 1) the velocity of tricuspid valve regurgitation of ≥3 m/s in the
      absence of pulmonary stenosis or 2)estimated right ventricular systolic pressure (RVSP)
      greater than 40 mm Hg, or RVSP/systemic systolic blood pressure greater than 0.5, any 3)
      cardiac shunt with bidirectional or right-to-left flow, 4) flat or left-deviated
      interventricular septal configuration and right ventricular hypertrophy with chamber
      dilation.

      Serum Biomarkers:

      Serum biomarkers like kallistatin, NT-ProBNP, gelsolin, homocysteine, cystatin C levels were
      measured only in the beginning of the study and not repeated in the following controls.

        1. Serum Kallistatin Levels Blood for kallistatin level was taken to the tubes centrifuged
           at 4000 rpm for 10 min at 4°C. The serum was kept at -80°C as frozen until required.
           Kallistatin levels were determined by ELISA (R&D Systems, Inc. Minneapolis, USA) as
           previously described [12].

        2. Plasma NT-ProBNP Levels Five ml blood sample was drawn from both patient and control
           groups for N terminal pro Brain natriuretic peptide (NT-ProBNP). Blood samples were
           centrifuged at +4°C and 1500 rpm for 5 minutes. Plasma part of the upper phase was taken
           in to another tube for NT-ProBNP calculation. Samples were preserved at -80°C till the
           study date. Later on, they were studied with ELISA method using Biomedica N-terminal pro
           BNP commercial kits (NT- ProBNP enzyme immuno assay kit Biomedica, Bratislava, Slovakia)
           and Elecsys® 1010 aoutoanalyzer (Roche Diagnostics, Basel, Switzerland). Results were
           expresses as fmol/ml (1fmol/ml=16.1pg/ml).

        3. Serum Gelsolin Levels:

           Venous blood samples of the healthy individuals and patients were drawn on admission.
           The blood samples were immediately placed in sterile etylene diamin tetra asetic acid
           test tubes and centrifuged at 2000-3000 rpm for 20 minutes at 4°C to collect plasma.
           Plasma was stored at -80°C until assayed. The concentration of gelsolin in plasma was
           analysed by enzyme-linked immunosorbent assay using commercial kits (Hangzhou
           Eastbiopharm Co., Ltd, Hangzhou, Zhejiang, China) in accordance with the manufacturer's
           instructions.

        4. Plasma Homocysteine Levels:

           Plasma Homocysteine was measured using an auto-biochemical analyzer (AU5800, Beckman
           Coulter Company, U.S.A.) by the enzymatic method. This method uses the S-adenosyl
           homocysteine (SAH) hydrolase reaction principle, in which SAH is hydrolyzed by
           hydrolytic enzymes into adenosine and Homocysteine; adenosine is immediately hydrolyzed
           into ammonia and hypoxanthine, and nicotinamide adenine dinucleotide (NADH) is converted
           to NAD by ammonia and glutamic dehydrogenase. The concentration of Homocysteine in the
           sample is proportional to the NADH transformation rate. The detection reagents were
           provided by DiaSys Diagnosis System GmbH (Shanghai) Co., Ltd.

        5. Serum Cystatin-C Levels:

      Cystatin C levels were determined with an immune nephelometry method on an ProSpec analyzer
      (BN ProSpec, Siemens, Frimley, United Kingdom) using latex enhanced particles coated with
      anti-cystatin C antibodies. The reference values for young healthy persons range from 0.53 to
      0.95 mg/l. The coefficient of variation was 1.8% within one run and 2.0% during
      reproducibility tests. Freezing and long-term storage up to 25 years has a small impact on
      stability of cystatin C [13].

      The study was approved by the local research Ethics Committee. All the parents were informed
      written consent were taken from each of them about participating in the study.

      Statistical analysis:

      Data analysis was performed using IBM SPSS Statistics Standard Concurrent User V 25 (IBM
      Corp., Armonk, New York, USA). Continuous variables were expressed either as mean ± standard
      deviation or median 25th-75th percentiles. Distribution of numerical data is evaluated by
      Shapiro Wilk normality test Q -Q graphics. Categorical variables were expressed as counts,
      proportions, and percentages. A Kruskal-Wallis test was used to determine whether or not
      there is a statistically significant difference between the medians of three or more
      independent groups with non-parametric values. If statistical significance was detected
      (p<0.05) Post Hoc Analysis - Tukey test was performed for pairwise comparisons. For the
      repeated measures analysis of a dependent group; Friedman test was used.
    


Study Type

Observational


Primary Outcome

Echocardiographic examination


Condition

Pulmonary Hypertension


Study Arms / Comparison Groups

 Preterm neonates with bronchopulmonary dysplasia with pulmonary hypertension
Description:  Preterm neonates who continued need for respiratory support persisting at 36 weeks corrected postmenstrual age and diagnosed with pulmonary hypertension on echocardiographic examination

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

59

Start Date

January 1, 2016

Completion Date

June 1, 2017

Primary Completion Date

January 1, 2017

Eligibility Criteria

        1. BPD patients with PHT

             Inclusion Criteria:

               -  Born ≤ 28 postmenstrual weeks

               -  Respiratory support persisting at 36 weeks corrected postmenstrual age.

               -  Echocardiographic examination consistent with pulmonary hypertension

          2. BPD patients without PHT

             Inclusion Criteria:

               -  Born ≤ 28 postmenstrual weeks

               -  Respiratory support persisting at 36 weeks corrected postmenstrual age.

               -  Normal echocardiographic examination

          3. Healty preterms

               -  Born ≤ 28 postmenstrual weeks

               -  Do not need respiratory support persisting at 36 weeks corrected postmenstrual
                  age

               -  Normal echocardiographic examination

        Exclusion Criteria:

          -  Congenital heart disease (with the exception of patent ductus arteriosus or patent
             foramen ovale)

          -  Structural lung and airway malformations (including tracheobrochomalacia)

          -  Congenital diaphragmatic hernia

          -  Chromosome abnormality
      

Gender

All

Ages

N/A - 3 Months

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

, , 



Administrative Informations


NCT ID

NCT05082272

Organization ID

6196


Responsible Party

Principal Investigator

Study Sponsor

Kayseri City Hospital


Study Sponsor

, , 


Verification Date

October 2021